ArticleJournal of clinical medicine2022
Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of angiotensin receptor neprilysin inhibitors in patients with STEMI: a systematic review and meta-analysis.Future cardiology · 2025Pooled it
- Prognostic performance of cardiogenic shock 4 proteins prediction model in infarct-related cardiogenic shock.ESC heart failure · 2026Trial
- Evaluating the effects of sacubitril/valsartan with ST-elevated myocardial infarction: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2026Article
- Predicting complications in emergency department patients with acute coronary syndrome - Existing risk scores versus a new logistic regression model.American heart journal plus : cardiology research and practice · 2026Article
- Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post-Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by Klotho.Journal of the American Heart Association · 2026Article
- Machine learning-based mortality risk prediction model for elderly diabetic patients with non-ST-segment elevation myocardial infarction using MIMIC-IV database.Scientific reports · 2025Article
- Article
- Cardiovascular comorbidities in hospitalized patients with hypertrophic cardiomyopathy and factors associated with a higher case-fatality rate.Future cardiology · 2025Article
- Real-world management of hypercholesterolemia in patients after acute coronary syndrome in Greece.Atherosclerosis plus · 2025Article
- Risk factors for cardiogenic shock incidence and mortality after acute myocardial infarction: a systematic review and meta-analysis.Communications medicine · 2025Article
- Article
- The impact of group II pulmonary hypertension on congestive heart failure patients admitted with ST elevation myocardial infarction, a nationwide study.Journal of thoracic disease · 2024Article
- Transient STEMI: Not to be Considered a Lesser Evil.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- Characteristics, Treatment Strategies and Outcome in Cardiogenic Shock Complicating Acute Myocardial Infarction: A Contemporary Dutch Cohort.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI). In AMI-CS, the ST segment deviation on ECG may be elevated (STEMI-CS) or non-elevated (NSTEMI-CS), which may influence prognosis. Our aim was to analyze the clinical profile, acute-phase prognosis, and long-term outcomes of CS relative to the ST pattern on admission. In a prospective registry of 4647 AMI patients admitted to the intensive cardiac care unit of a university hospital between 2010 and 2019, we compared the clinical characteristics, 30-days case fatality, and long-term outcomes of AMI-CS, based on the presence of ST-segment deviation. AMI-CS developed in 239 (5.1%) patients (26.4% women): 190 (79.5%) STEMI-CS and 49 (20.5%) NSTEMI-CS. The mean age was 69.7 years. The STEMI-CS patients had larger infarcts and more mechanical complications than the NSTEMI-CS patients. The NSTEMI-CS patients had a greater prevalence of hypertension, diabetes, peripheral vascular disease, previous cardiovascular comorbidities, three-vessel disease, and left main disease than the STEMI-CS patients. The STEMI-CS patients had higher 30-day mortality than the NSTEMI-CS (59.5% vs. 36.7%;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.